WO2008095284A1 - Comprimés d'épinéphrine à dissolution rapide pour administration orale ou sublinguale - Google Patents

Comprimés d'épinéphrine à dissolution rapide pour administration orale ou sublinguale Download PDF

Info

Publication number
WO2008095284A1
WO2008095284A1 PCT/CA2008/000197 CA2008000197W WO2008095284A1 WO 2008095284 A1 WO2008095284 A1 WO 2008095284A1 CA 2008000197 W CA2008000197 W CA 2008000197W WO 2008095284 A1 WO2008095284 A1 WO 2008095284A1
Authority
WO
WIPO (PCT)
Prior art keywords
epinephrine
sublingual
tablet
buccal
tablets
Prior art date
Application number
PCT/CA2008/000197
Other languages
English (en)
Inventor
Mutasem Rawas-Qalaji
Keith Simons
Xiaochen Gu
Estelle Simons
Original Assignee
University Of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Manitoba filed Critical University Of Manitoba
Publication of WO2008095284A1 publication Critical patent/WO2008095284A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des formulations pour des comprimés d'épinéphrine à dissolution rapide pouvant être préparés pour administration orale ou sublinguale. Lesdits comprimés d'épinéphrine à dissolution rapide peuvent produire des concentrations plasmiques d'épinéphrine sensiblement équivalentes à celles obtenues par des formes posologiques injectables traditionnelles, comprenant l'épinéphrine injectée par voie sous-cutanée ou intramusculaire.
PCT/CA2008/000197 2007-02-07 2008-01-31 Comprimés d'épinéphrine à dissolution rapide pour administration orale ou sublinguale WO2008095284A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/672,503 2007-02-07
US11/672,503 US20070202163A1 (en) 2005-09-09 2007-02-07 Fast-disintegrating epinephrine tablets for buccal or sublingual administration

Publications (1)

Publication Number Publication Date
WO2008095284A1 true WO2008095284A1 (fr) 2008-08-14

Family

ID=39682635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2008/000197 WO2008095284A1 (fr) 2007-02-07 2008-01-31 Comprimés d'épinéphrine à dissolution rapide pour administration orale ou sublinguale

Country Status (2)

Country Link
US (1) US20070202163A1 (fr)
WO (1) WO2008095284A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144865A2 (fr) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Procédés de traitement de troubles gastro-intestinaux
EP2861224A4 (fr) * 2012-06-15 2015-11-18 Univ Nova Southeastern Nanoparticules d'épinéphrine, procédé pour les fabriquer et procédés pour les utiliser pour le traitement d'affections répondant à l'épinéphrine
US10159656B2 (en) 2005-09-09 2018-12-25 Nova Southeastern University Methods for use of epinephrine fine particles for treatment of conditions responsive to epinephrine
US10568836B2 (en) 2011-10-21 2020-02-25 Nova Southeastern University Epinephrine nanoparticles encapsulated with chitosan and tripolyphosphate, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US10682316B2 (en) 2005-09-09 2020-06-16 Nova Southeastern University Methods for fabrication of epinephrine bitartrate nanoparticles and epinephrine bitartrate nanoparticles fabricated thereby
US11229613B2 (en) 2013-03-22 2022-01-25 Nova Southeastern University Compositions including epinephrine microcrystals
US11413296B2 (en) 2005-11-12 2022-08-16 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
KR101626873B1 (ko) * 2007-10-01 2016-06-02 라보라토리오스 레스비, 에스.엘. 구강붕해정제
US10350364B2 (en) 2009-11-11 2019-07-16 Windgap Medical, Inc. Portable Drug Mixing and Delivery Device and Associated Methods
AU2014232211B2 (en) 2013-03-15 2017-05-25 Windgap Medical, Inc. Portable drug mixing and delivery system and method
US10569017B2 (en) 2013-03-15 2020-02-25 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
US9907910B2 (en) 2013-03-15 2018-03-06 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
US20200085765A1 (en) * 2014-07-03 2020-03-19 Darren Rubin Safer and more effective methods of transmucosal, including intranasal, delivery for raising blood pressure and stimulating the body
US9925335B2 (en) 2014-08-18 2018-03-27 Windgap Medical, Inc Portable drug mixing and delivery device and associated methods
US11116903B2 (en) 2014-08-18 2021-09-14 Windgap Medical, Inc Compression seal for use with a liquid component storage vial of an auto-injector
WO2016190980A1 (fr) 2015-04-15 2016-12-01 Windgap Medical, Llc Capuchon d'actionnement amovible destiné à être utilisé avec un ensemble auto-injecteur
JP6580777B2 (ja) 2015-08-13 2019-09-25 ウィンドギャップ メディカル， インコーポレイテッド 無菌特徴を有する混合及び注入装置
BR112018072539A2 (pt) * 2016-05-05 2019-03-26 Aquestive Therapeutics, Inc. composições de epinefrina de administração aumentada
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
EP3452024A1 (fr) * 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Compositions pharmaceutiques à perméation améliorée
CN110418639B (zh) * 2016-11-13 2023-06-02 艾奥诺医药有限公司 肾上腺素前药的舌下或口含给药制剂
AU2017379094B2 (en) 2016-12-23 2023-08-24 Kaleo, Inc. Medicament delivery device and methods for delivering drugs to infants and children
JOP20190241B1 (ar) 2017-04-17 2023-09-17 Hikma Pharmaceuticals Usa Inc مستحضرات رذاذ إبينيفرين
AU2018329496A1 (en) 2017-09-06 2020-03-19 pHase Pharmaceuticals LLC Sublingual epinephrine tablets
EA202090637A1 (ru) * 2017-09-08 2020-06-29 Инсайгнис Терапьютикс, Инк. Способы применения дипивефрина
WO2019067670A1 (fr) * 2017-09-27 2019-04-04 Aquestive Therapeutics, Inc. Compositions d'épinéphrine et de promédicament à administration améliorée
CN113613630A (zh) 2019-03-01 2021-11-05 因斯格尼斯疗法有限公司 地匹福林口腔崩解片剂制剂
CA3178769A1 (fr) 2020-05-18 2021-11-25 Jonas Savmarker Nouvelle composition pharmaceutique pour une administration de medicament
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028247A1 (fr) * 2005-09-09 2007-03-15 University Of Manitoba Comprimes d'epinephrine a desintegration rapide destines a une administration orale ou sublinguale

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028247A1 (fr) * 2005-09-09 2007-03-15 University Of Manitoba Comprimes d'epinephrine a desintegration rapide destines a une administration orale ou sublinguale

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GU X. ET AL.: "Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study", BIOPHARMACEUTICS & DRUG DISPOSITION, vol. 23, no. 5, 2002, pages 213 - 216 *
RAWAS-QALAJI M.M .ET AL.: "Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability?", DISPOSITION, vol. 27, no. 9, 2006, pages 427 - 435 *
RAWAS-QALAJI M.M. ET AL.: "Fast-disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics", AAPS PHARMSCITECH., vol. 7, no. 2, 2006, pages E1 - E7, XP003009194, DOI: doi:10.1208/pt070241 *
RAWAS-QALAJI M.M. ET AL.: "Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 117, no. 2, 2006, pages 398 - 403, XP005275425 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10159656B2 (en) 2005-09-09 2018-12-25 Nova Southeastern University Methods for use of epinephrine fine particles for treatment of conditions responsive to epinephrine
US10682316B2 (en) 2005-09-09 2020-06-16 Nova Southeastern University Methods for fabrication of epinephrine bitartrate nanoparticles and epinephrine bitartrate nanoparticles fabricated thereby
US11413296B2 (en) 2005-11-12 2022-08-16 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2010144865A2 (fr) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Procédés de traitement de troubles gastro-intestinaux
US10568836B2 (en) 2011-10-21 2020-02-25 Nova Southeastern University Epinephrine nanoparticles encapsulated with chitosan and tripolyphosphate, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
EP2861224A4 (fr) * 2012-06-15 2015-11-18 Univ Nova Southeastern Nanoparticules d'épinéphrine, procédé pour les fabriquer et procédés pour les utiliser pour le traitement d'affections répondant à l'épinéphrine
US10251849B2 (en) 2012-06-15 2019-04-09 Nova Southeastern University Sublingual compositions including epinephrine nanoparticles
US11246843B2 (en) 2012-06-15 2022-02-15 Nova Southeastern University Method for increasing plasma concentration of epinephrine in a subject having a condition responsive to epinephrine
US11229613B2 (en) 2013-03-22 2022-01-25 Nova Southeastern University Compositions including epinephrine microcrystals

Also Published As

Publication number Publication date
US20070202163A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
US20070202163A1 (en) Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20070059361A1 (en) Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20070293582A1 (en) Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
US8092832B2 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
US20070293581A1 (en) Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
US8119158B2 (en) Effervescent oral fentanyl dosage form and methods of administering fentanyl
EP2124900B1 (fr) Formes posologiques solides se désintégrant oralement comprenant de la progestine et leurs procédés de fabrication et d'utilisation
US9492541B2 (en) Phenylepherine containing dosage form
US20070196494A1 (en) Low-friability, patient-friendly orally disintegrating formulations
US20090280172A1 (en) Galenic formulations of organic compounds
JP5064226B2 (ja) 不眠症の治療において有用な新規な製剤処方
AU2002364468C1 (en) Solid orally-dispersible pharmaceutical formulation
WO2006017540A2 (fr) Compositions de pilocarpine et procedes d'utilisation associes
US20130274342A1 (en) Compositions and methods for treating cough
US7811604B1 (en) Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
JP4090997B2 (ja) ペリンドプリルの口内分散性薬剤組成物
WO2022150597A1 (fr) Administration orale de kétamine
EP2248516A1 (fr) Compositions pharmaceutiques d'emoxypine à désintégration orale
JP2000095707A (ja) 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物
US20100227933A1 (en) Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase b inhibitors
US20240009145A1 (en) Compositions of aspirin and ketamine
US20230225994A1 (en) Sublingual epinephrine formulations and methods of use
Vishnu Formulation and Evaluvation of Fast Dissolving Films of Isosorbide Mononitrate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08714534

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08714534

Country of ref document: EP

Kind code of ref document: A1